EUCTR2007-002160-10-FR进行中（未招募）1 期
A prospective, open-label, single arm, multinational, multi-centre, flexible dose, extension study of the SCoP 99824 with sertindole for patients suffering from schizophrenia
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.The patient and/or legally acceptable representative is able to read and understand the Patient Information Sheet for Study 12009A.
- •2.The patient has signed the Informed Consent Form for Study 12009A.
- •3.The patient has taken part in SCoP Study 99824 study.
- •4.The patient still fulfils the EU SPC requirements for sertindole, including pregnancy exclusion and ECG parameters warnings.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.The patient has withdrawn before the end of SCoP 99824 study.
- •The patient has become homeless.
- •3.The patient is going to participate in another clinical trial at the same time.
- •4.The patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
研究者
相似试验
进行中（未招募）
1 期
Open-label, single arm trial of BI 695502 in patients with previously untreated locally advanced or metastatic colorectal cancerPreviously untreated locally advanced or metastaticcolorectal cancerMedDRA version: 18.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-003718-25-ESBoehringer Ingelheim International GmbH120
进行中（未招募）
2 期
A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted with Ritonavir (RTV) Liquid with an Optimized NRTI Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years. (Pediatric Atazanavir International Clinical Evaluation: the PRINCE I study)RBR-3vmkt2Bristol-Myers Squibb
进行中（未招募）
不适用
Safety Sudy of Atazanavir Capsules in the Treatment of HIV in Patients Ages 6 - 18 YearsHIV in paediatric populationEUCTR2011-003300-21-Outside-EU/EEABristol-Myers Squibb Company113
进行中（未招募）
1 期
A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate theSafety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted withRitonavir (RTV) Liquid with an Optimized NRTI Background Therapy, in HIV InfectedPediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years. (PediatricAtazanavir International Clinical Evaluation: the PRINCE I study)Revised Protocol 01, incorporating Protocol Amendment 01. - the PRINCE I studyEUCTR2009-016361-28-PLBristol-Myers Squibb International Corporation100
进行中（未招募）
不适用
A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted with Ritonavir (RTV) Liquid with an Optimized NRTI Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years. (Pediatric Atazanavir International Clinical Evaluation: the PRINCE I study) Revised Protocol 01, incorporating Protocol Amendment 01. - the PRINCE I studyHIV pediatricMedDRA version: 9.1Level: LLTClassification code 10020161EUCTR2009-016361-28-ITBristol-Myers Squibb International Corporation100